Skip to main content

Overactive Bladder (OAB)

3
Pipeline Programs
9
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
Detrol LAPhase 41 trial
FesoterodineN/A1 trial
Active Trials
NCT01936870Completed2,521Est. May 2016
NCT00282932Completed600Est. May 2007
Sandoz
SandozAustria - Kundl
1 program
1
DarifenacinPhase 41 trial
Active Trials
NCT00366002Completed500Est. Sep 2007
Kissei Pharmaceutical
Kissei PharmaceuticalJapan - Matsumoto City
1 program
1
KUC-7483Phase 21 trial
Active Trials
NCT00742833Completed400
Fempulse
2 programs
Device GroupN/A1 trial
FemPulse SystemN/A1 trial
Active Trials
NCT07195656Recruiting151Est. Dec 2027
NCT06885099Completed11Est. Jul 2025
Astellas
AstellasChina - Shenyang
1 program
Non-InterventionalN/A1 trial
Active Trials
NCT03903094Completed6,295,279Est. May 2022
Enterprise Therapeutics
1 program
RiSolveN/A1 trial
Active Trials
NCT07206446Not Yet Recruiting45Est. Dec 2025
Salvat
SalvatFL - Miami
1 program
SVT-40776PHASE_21 trial
Active Trials
NCT00507169CompletedEst. Sep 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
SandozDarifenacin
PfizerDetrol LA
SalvatSVT-40776
FempulseDevice Group
Enterprise TherapeuticsRiSolve
FempulseFemPulse System
AstellasNon-Interventional
PfizerFesoterodine

Clinical Trials (9)

Total enrollment: 6,299,507 patients across 9 trials

NCT00366002SandozDarifenacin

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

Start: Jun 2006Est. completion: Sep 2007500 patients
Phase 4Completed
NCT00282932PfizerDetrol LA

Detrol LA In Men With Overactive Bladder.

Start: Jan 2006Est. completion: May 2007600 patients
Phase 4Completed
NCT00742833Kissei PharmaceuticalKUC-7483

A Phase II Study of KUC-7483 in Patients With Overactive Bladder

400 patients
Phase 2Completed
NCT00507169SalvatSVT-40776

SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

Start: Sep 2006Est. completion: Sep 2007
Phase 2Completed
NCT07195656FempulseDevice Group

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

Start: Sep 2025Est. completion: Dec 2027151 patients
N/ARecruiting
NCT07206446Enterprise TherapeuticsRiSolve

A Prospective Evaluation of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women: The RiSolve Trial

Start: Sep 2025Est. completion: Dec 202545 patients
N/ANot Yet Recruiting
NCT06885099FempulseFemPulse System

Ease of Use Study of the FemPulse System

Start: Feb 2025Est. completion: Jul 202511 patients
N/ACompleted
NCT03903094AstellasNon-Interventional

A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden

Start: Mar 2019Est. completion: May 20226,295,279 patients
N/ACompleted
NCT01936870PfizerFesoterodine

Drug Use Investigation for Toviaz

Start: Oct 2013Est. completion: May 20162,521 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 6,299,507 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.